Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVT 302 phase II smoking cessation study with optional nicotine replacement
2008-002472-99Phase 2Completed
- Sponsor
- Evotec SE
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sembragiline in nicotine dependence (4 arms), sponsored by Evotec SE. Primary endpoints: 4-week continuous quit rate during Weeks 5 to 8 and Safety and tolerability. Started Jun 2008; status: completed.
02
Drugs
sembragiline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2008-002472-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002472-99.